Sukumar Nagendran

Sukumar Nagendran is a declared insider at 3 companies (board member); the most frequent names are AveXis, Inc., Taysha Gene Therapies, Inc. and Solid Biosciences Inc. We count 70 filings; the first trade dates from 3 April 2017 and the latest from 10 July 2026.

In open-market terms, that means 2 purchases worth €74k on one side and 46 sales worth €4.1M on the other. On balance, insiders were net sellers of €4.0M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 4 share grants and 16 option exercises. So far in 2026, the count stands at no purchases and 3 sales.

The newest entry dates from 10 July 2026: an open-market sale of €1.1M, in Taysha Gene Therapies, Inc. The clock since the last published purchase (18 May 2023) now reads 1,252 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.